Firm News
Wiggin and Dana Client Notable Labs, Inc. Acquires Worldwide Development and Commercialization Rights to Volasertib
Wiggin and Dana represented its client Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, in connection with the acquisition of development and commercialization rights in Volasertib from Oncoheroes Biosciences Inc. for uses that include leukemias and lymphomas, including acute myeloid leukemia (AML).ย Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in AML and other tumor types with significant unmet medical needs. Notable intends to leverage its proprietary predictive precision medicines platform to accelerate clinical trial timelines and maximize patient outcomes.ย Partners Patti Melick and Jonathan Harris, and Associate Madeleine Tavcar are proud and grateful to have had the opportunity to contribute to the success of this transaction.
To read the official press release, please click here.